



**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 55009

**Title:** Statins in risk-reduction and treatment of cancer

**Reviewer’s code:** 02979225

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer’s Country/Territory:** Italy

**Author’s Country/Territory:** Romania

**Manuscript submission date:** 2020-02-28

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2020-02-29 07:53

**Reviewer performed review:** 2020-02-29 09:09

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

Authors submitted a review entitled "Statins in risk-reduction and treatment of cancer". The topic is very interesting, and the review include most of current evidence. The manuscript is too long, authors described the biochemical characteristics of statins in details, so the text does not reflect the proposed title. Authors should remove the paragraphs about the statins pharmacology and properties, induction of NO synthesis,, anti-inflammatory properties,, antioxidant properties, plaque stabilization properties, statins and bone metabolism, side effects of statins. Authors should focus on the reviews purpose about the role of statins on cancer. Furthermore, authors should summarize paragrafs about in vitro and in vivo studies, these paragraphs are too long making it difficult to read.



**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 55009

**Title:** Statins in risk-reduction and treatment of cancer

**Reviewer’s code:** 02942798

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Chief Doctor, Professor

**Reviewer’s Country/Territory:** Slovakia

**Author’s Country/Territory:** Romania

**Manuscript submission date:** 2020-02-28

**Reviewer chosen by:** Ruo-Yu Ma

**Reviewer accepted review:** 2020-04-24 17:02

**Reviewer performed review:** 2020-04-24 19:42

**Review time:** 2 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input checked="" type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://www.wjgnet.com**

Dear sir, thank you to select me to review manuscript Barbalata CI et al. Statins in risk-reduction and treatment of cancer. Although the topic of the manuscript is interesting, the text is too extensive and very difficult to read. The biggest problem is the absence of a comprehensive clinical view of the statin effect on oncological diseases. The chapters Induction of NO synthesis, Antiinflammatory properties, Antioxidant properties, Plaque stabilisation properties, Statin and bone metabolism, Side effects of statins have no connection with the issue of statins in oncology. Chapters In vitro studies and In vivo preclinical studies should be shortened and chapters evaluating statinis in clinical oncology should be written more consistently (for example: there are no data about impact of statins on HCC clinical course). If the authors want to keep the article in this mode, it will be better to send it to a more theoretically focused oncological journal.